METABOLIC GLUTAMATE RECEPTOR 5 MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-178958 |   Pharmaceuticals and Medical

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Metabolic glutamate receptor 5 Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET

7.1 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA METABOLIC GLUTAMATE RECEPTOR 5 MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Johnson & Johnson

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Eisai Co Ltd

16.3 Bristol-Myers Squibb Company

16.4 Richter Gedeon Nyrt

16.5 Novartis AG

16.6 Aevi Genomic Medicine Inc

16.7 Eli Lilly and Company

16.8 Sumitomo Dainippon Pharma Co Ltd

16.9 Addex Therapeutics Ltd

16.10 Merz Pharma GmbH & Co KgaA

16.11 Toray Industries Inc

16.12 Heptares Therapeutics Ltd

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Major Types Covered
Dipraglurant ER
BMS-952048
Other types
BMS-955829
Alloswitch-1

Major Downstream Industry Covered
Alzheimer's disease
Other applications
Severe depression
Alcohol addiction

Companies

Johnson & Johnson
Eisai Co Ltd
Bristol-Myers Squibb Company
Richter Gedeon Nyrt
Novartis AG
Aevi Genomic Medicine Inc
Eli Lilly and Company
Sumitomo Dainippon Pharma Co Ltd
Addex Therapeutics Ltd
Merz Pharma GmbH & Co KgaA
Toray Industries Inc
Heptares Therapeutics Ltd

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.